# Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

> **NCT04383743** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 17 (actual)

## Conditions studied

- Stage II Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
- Muscle Invasive Bladder Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Doxorubicin
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Pegfilgrastim
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Radical Cystectomy
- **DRUG:** Vinblastine Sulfate

## Key facts

- **NCT ID:** NCT04383743
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2024-06-17
- **Final completion:** 2025-03-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04383743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04383743, "Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04383743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*